EDSA
Edesa Biotech, Inc.
Price Chart
Latest Quote
$7.35
+0.47 (+6.83%)
Current Price
| Previous Close | $6.88 |
| Open | $6.94 |
| Day High | $7.60 |
| Day Low | $6.56 |
| Volume | 258,618 |
Stock Information
| Shares Outstanding | 8.89M |
| Cash Equivalents | $10.00M |
| Net Income | $-10.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $65.36M |
| EPS (TTM) | $-1.30 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $63.73M |
| Income | $-10.44M |
| Book/sh | $0.20 |
| Cash/sh | $1.13 |
| Employees | 17 |
Financial Ratios
| Quick Ratio | 4.67 |
| Current Ratio | 4.76 |
Returns & Margins
| ROA | -47.73% |
| ROE | -81.16% |
Ownership
| Insider Ownership | 20.22% |
| Institutional Ownership | 42.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 35.85 |
Analyst Data
| Recommendation | none |
| Target Price | $14.00 |
Technical Indicators
| SMA20 | $7.02 |
| SMA50 | $9.51 |
| SMA200 | $4.31 |
| RSI | 51.18 |
| ATR | 1.0193 |
| Shares Float | 5.84M |
| Short Float | 2.91% |
| Short Ratio | 0.48 |
| Volatility | 1.07 |
| Rel Volume | 0.93 |
Performance History
| Week | +30.09% |
| Month | -38.49% |
| Quarter | +1.66% |
| 6 Months | +393.29% |
| YTD | +390.00% |
| Year | +265.67% |
| 3 Years | +20.69% |
| 5 Years | -82.02% |
| 10 Years | -99.16% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $7.35 | 258,400 |
| 2026-06-17 | $6.88 | 223,900 |
| 2026-06-16 | $6.27 | 194,700 |
| 2026-06-15 | $5.94 | 185,900 |
| 2026-06-12 | $5.80 | 175,000 |
| 2026-06-11 | $5.65 | 508,900 |
| 2026-06-10 | $5.21 | 149,900 |
| 2026-06-09 | $4.94 | 297,400 |
| 2026-06-08 | $5.37 | 303,400 |
| 2026-06-05 | $5.46 | 764,900 |
| 2026-06-04 | $7.09 | 145,300 |
| 2026-06-03 | $6.86 | 150,200 |
| 2026-06-02 | $6.83 | 236,400 |
| 2026-06-01 | $6.69 | 363,800 |
| 2026-05-29 | $7.22 | 246,600 |
| 2026-05-28 | $7.86 | 179,000 |
| 2026-05-27 | $7.97 | 629,900 |
| 2026-05-26 | $9.70 | 238,900 |
| 2026-05-22 | $10.46 | 114,700 |
| 2026-05-21 | $10.87 | 212,900 |
| 2026-05-20 | $10.93 | 398,400 |
| 2026-05-19 | $11.95 | 1,072,300 |
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
đ° Latest News
Sector Update: Healthcare Stocks Gain Friday Afternoon
MT Newswires âĸ 2026-06-05T17:50:31ZTop Midday Stories: Lululemon Down After Fiscal Q1 Results; Amazon Engineers Criticize AI Spending; Hoffman to Exit Microsoft Board
MT Newswires âĸ 2026-06-05T16:07:36ZEdesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying
Simply Wall St. âĸ 2026-04-23T10:49:22Z
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment
Insider Monkey âĸ 2026-04-20T14:14:46Z
BC-Most Active Stocks
Associated Press Finance âĸ 2026-02-24T15:30:18ZFavourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock
Simply Wall St. âĸ 2025-10-28T11:20:57Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | - |
| Cost Of Revenue | - | - | - | - |
| Expenses | ||||
| Total Expenses | $7,127,672 | $6,316,467 | $8,641,719 | $17,590,533 |
| Other Income Expense | $-59,609 | $-6,276 | $-21,742 | $-21,114 |
| Net Non Operating Interest Income Expense | $2,558 | $153,498 | $289,846 | $63,523 |
| Operating Expense | $7,127,672 | $6,316,467 | $8,641,719 | $17,590,533 |
| Other Operating Expenses | $-783,894 | $-698,277 | $-581,039 | $-780,257 |
| General And Administrative Expense | $4,242,828 | $4,132,777 | $4,428,209 | $5,035,456 |
| Other Non Operating Income Expenses | - | $14,766 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 |
| Net Interest Income | $2,558 | $153,498 | $289,846 | $63,523 |
| Interest Income | $2,558 | $153,498 | $289,846 | $63,523 |
| Normalized Income | $-7,134,855 | $-6,152,159 | $-8,361,370 | $-17,533,344 |
| Net Income From Continuing And Discontinued Operation | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 |
| Total Operating Income As Reported | $-7,911,566 | $-7,014,744 | $-9,222,758 | $-18,370,790 |
| Net Income Common Stockholders | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 |
| Net Income | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 |
| Net Income Including Noncontrolling Interests | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 |
| Net Income Continuous Operations | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 |
| Pretax Income | $-7,184,723 | $-6,169,245 | $-8,373,615 | $-17,548,124 |
| Interest Income Non Operating | $2,558 | $153,498 | $289,846 | $63,523 |
| Operating Income | $-7,127,672 | $-6,316,467 | $-8,641,719 | $-17,590,533 |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-1.27 | $-1.93 | $-2.93 | $-7.35 |
| Basic EPS | $-1.27 | $-1.93 | $-2.93 | $-7.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $-8,941 | $-3,156 | $-8,697 | $-5,534 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,948,790 | $-6,109,376 | $-8,436,506 | $-17,451,231 |
| Total Unusual Items | $-59,609 | $-21,042 | $-21,742 | $-21,114 |
| Total Unusual Items Excluding Goodwill | $-59,609 | $-21,042 | $-21,742 | $-21,114 |
| Reconciled Depreciation | $119,273 | $186,049 | $183,471 | $118,188 |
| EBITDA (Bullshit earnings) | $-7,008,399 | $-6,130,418 | $-8,458,248 | $-17,472,345 |
| EBIT | $-7,127,672 | $-6,316,467 | $-8,641,719 | $-17,590,533 |
| Diluted Average Shares | $5,676,708 | $3,197,423 | $2,858,929 | $2,380,287 |
| Basic Average Shares | $5,676,708 | $3,197,423 | $2,858,929 | $2,380,287 |
| Diluted NI Availto Com Stockholders | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 |
| Tax Provision | $800 | $800 | $800 | $800 |
| Gain On Sale Of Security | $-59,609 | $-21,042 | $-21,742 | $-21,114 |
| Research And Development | $3,668,738 | $2,881,967 | $4,794,549 | $13,335,334 |
| Selling General And Administration | $4,242,828 | $4,132,777 | $4,428,209 | $5,035,456 |
| Other Gand A | $4,242,828 | $4,132,777 | $4,428,209 | $5,035,456 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $10,474,306 | $-97,693 | $4,868,780 | $7,110,097 |
| Total Assets | $13,530,518 | $3,813,982 | $8,890,437 | $11,575,728 |
| Total Non Current Assets | $2,017,642 | $2,138,360 | $2,453,585 | $2,483,815 |
| Non Current Prepaid Assets | $39,966 | $41,151 | $173,490 | $171,464 |
| Goodwill And Other Intangible Assets | $1,977,676 | $2,078,848 | $2,180,020 | $2,281,192 |
| Other Intangible Assets | $1,977,676 | $2,078,848 | $2,180,020 | $2,281,192 |
| Current Assets | $11,512,876 | $1,675,622 | $6,436,852 | $9,091,913 |
| Other Current Assets | $77,838 | $367,394 | $448,912 | $745,543 |
| Receivables | $642,866 | $270,908 | $626,543 | $1,255,451 |
| Accounts Receivable | $642,866 | $270,908 | $626,543 | $1,255,451 |
| Cash Cash Equivalents And Short Term Investments | $10,792,172 | $1,037,320 | $5,361,397 | $7,090,919 |
| Cash And Cash Equivalents | $10,792,172 | $1,037,320 | $5,361,397 | $7,090,919 |
| Prepaid Assets | - | - | - | $745,543 |
| Debt | ||||
| Total Debt | $0 | $19,867 | $94,487 | $18,975 |
| Long Term Debt And Capital Lease Obligation | - | $0 | $19,773 | $0 |
| Current Debt And Capital Lease Obligation | - | $19,867 | $74,714 | $18,975 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,078,536 | $1,832,827 | $1,841,637 | $2,184,439 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $19,773 | $43,662 |
| Current Liabilities | $1,078,536 | $1,832,827 | $1,821,864 | $2,140,777 |
| Payables And Accrued Expenses | $1,078,536 | $1,812,960 | $1,747,150 | $2,121,802 |
| Tradeand Other Payables Non Current | - | - | $0 | $43,662 |
| Equity | ||||
| Common Stock Equity | $3,191,786 | $1,981,155 | $7,048,800 | $9,391,289 |
| Preferred Stock Equity | $9,260,196 | - | - | - |
| Total Equity Gross Minority Interest | $12,451,982 | $1,981,155 | $7,048,800 | $9,391,289 |
| Stockholders Equity | $12,451,982 | $1,981,155 | $7,048,800 | $9,391,289 |
| Gains Losses Not Affecting Retained Earnings | $-165,771 | $-242,613 | $-214,648 | $-213,602 |
| Other Equity Adjustments | $-165,771 | $-242,613 | $-214,648 | $-213,602 |
| Retained Earnings | $-65,910,974 | $-58,589,013 | $-52,418,968 | $-44,044,553 |
| Other Equity Interest | - | - | - | $-213,602 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $7,141,783 | $3,247,389 | $3,075,473 | $2,380,287 |
| Share Issued | $7,141,783 | $3,247,389 | $3,075,473 | $2,380,287 |
| Tangible Book Value | $1,214,110 | $-97,693 | $4,868,780 | $7,110,097 |
| Invested Capital | $3,191,786 | $1,981,155 | $7,048,800 | $9,391,289 |
| Working Capital | $10,434,340 | $-157,205 | $4,614,988 | $6,951,136 |
| Capital Lease Obligations | $0 | $19,867 | $94,487 | $18,975 |
| Total Capitalization | $12,451,982 | $1,981,155 | $7,048,800 | $9,391,289 |
| Additional Paid In Capital | $14,753,110 | $13,576,757 | $13,039,265 | $11,176,345 |
| Capital Stock | $63,775,617 | $47,236,024 | $46,643,151 | $42,473,099 |
| Common Stock | $54,515,421 | $47,236,024 | $46,643,151 | $42,473,099 |
| Preferred Stock | $9,260,196 | $0 | - | - |
| Current Capital Lease Obligation | $0 | $19,867 | $74,714 | $18,975 |
| Net PPE | $0 | $18,361 | $100,075 | $31,159 |
| Gross PPE | $0 | $18,361 | $143,921 | $70,677 |
| Long Term Capital Lease Obligation | - | $0 | $19,773 | $0 |
| Accumulated Depreciation | - | $-52,548 | $-43,846 | $-39,518 |
| Other Properties | - | $18,361 | $91,373 | $18,465 |
| Machinery Furniture Equipment | - | $52,548 | $52,548 | $52,212 |
| Buildings And Improvements | - | - | - | $18,465 |
| Properties | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,322,262 | $-4,890,205 | $-6,636,483 | $-12,284,958 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,322,262 | $-4,890,205 | $-6,636,483 | $-12,279,302 |
| Cash Flow From Continuing Operating Activities | $-7,322,262 | $-4,890,205 | $-6,636,483 | $-12,279,302 |
| Investing Activities | ||||
| Investing Cash Flow | - | - | $0 | $-5,656 |
| Cash Flow From Continuing Investing Activities | - | - | $0 | $-5,656 |
| Capital Expenditure | - | - | - | $-5,656 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $17,598,454 | $729,387 | $4,345,017 | $11,957,687 |
| Financing Cash Flow | $17,030,898 | $592,031 | $4,830,111 | $11,629,628 |
| Cash Flow From Continuing Financing Activities | $17,030,898 | $592,031 | $4,830,111 | $11,629,628 |
| Net Other Financing Charges | $-544,110 | $-107,824 | $-285,438 | $-328,059 |
| Net Preferred Stock Issuance | $9,880,820 | $0 | - | - |
| Preferred Stock Issuance | $9,880,820 | $0 | - | - |
| Net Common Stock Issuance | $7,717,634 | $729,387 | $4,345,017 | $11,957,687 |
| Common Stock Issuance | $7,717,634 | $729,387 | $4,345,017 | $11,957,687 |
| Other | ||||
| Repayment Of Debt | $0 | $-29,532 | $0 | - |
| End Cash Position | $10,792,172 | $1,037,320 | $5,361,397 | $7,090,919 |
| Beginning Cash Position | $1,037,320 | $5,361,397 | $7,090,919 | $7,839,259 |
| Effect Of Exchange Rate Changes | $46,216 | $-25,903 | $76,850 | $-93,010 |
| Changes In Cash | $9,708,636 | $-4,298,174 | $-1,806,372 | $-655,330 |
| Proceeds From Stock Option Exercised | $-23,446 | $0 | $770,532 | $0 |
| Net Issuance Payments Of Debt | $0 | $-29,532 | $0 | - |
| Net Short Term Debt Issuance | $0 | $-29,532 | - | - |
| Short Term Debt Payments | $0 | $-29,532 | - | - |
| Change In Working Capital | $-985,654 | $571,065 | $308,004 | $2,890,800 |
| Change In Payables And Accrued Expense | $-715,499 | $17,590 | $-556,270 | $882,843 |
| Change In Prepaid Assets | $107,832 | $197,136 | $301,504 | $-19,497 |
| Change In Receivables | $-377,987 | $356,339 | $562,770 | $2,027,454 |
| Stock Based Compensation | $729,642 | $537,492 | $1,246,457 | $2,260,634 |
| Depreciation Amortization Depletion | $119,273 | $186,049 | $183,471 | $118,188 |
| Depreciation And Amortization | $119,273 | $186,049 | $183,471 | $118,188 |
| Net Income From Continuing Operations | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 |
| Net Long Term Debt Issuance | - | $-29,532 | $0 | - |
| Long Term Debt Payments | - | $-29,532 | $0 | - |
| Other Non Cash Items | - | $-14,766 | - | - |
| Net PPE Purchase And Sale | - | - | $0 | $-5,656 |
| Purchase Of PPE | - | - | $0 | $-5,656 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Net Investment Purchase And Sale | - | - | - | - |
| Sale Of Investment | - | - | - | - |
| Purchase Of Investment | - | - | - | - |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Purchase Of Intangibles | - | - | - | - |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-06-17